DS
XERS icon

David Shaw’s Xeris Biopharma Holdings XERS Stock Holding History

David Shaw’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.8M Buy
7,804,758
+15,947
+0.2% +$102K 0.03% 657
2026
Q1 		$45.2M Buy
7,788,811
+213,961
+3% +$1.42M 0.03% 704
2025
Q4 		$59.5M Buy
7,574,850
+1,734,964
+30% +$13.7M 0.03% 631
2025
Q3 		$47.5M Buy
5,839,886
+2,004,479
+52% +$13.3M 0.03% 685
2025
Q2 		$17.9M Buy
3,835,407
+783,035
+26% +$3.59M 0.01% 1105
2025
Q1 		$16.8M Buy
3,052,372
+1,688,920
+124% +$6.82M 0.01% 1050
2024
Q4 		$4.62M Buy
1,363,452
+378,437
+38% +$1.22M ﹤0.01% 2044
2024
Q3 		$2.81M Buy
985,015
+466,991
+90% +$1.2M ﹤0.01% 2429
2024
Q2 		$1.17M Sell
518,024
-188,987
-27% -$381K ﹤0.01% 3084
2024
Q1 		$1.56M Sell
707,011
-347,599
-33% -$899K ﹤0.01% 2804
2023
Q4 		$2.48M Buy
1,054,610
+179,200
+20% +$331K ﹤0.01% 2504
2023
Q3 		$1.63M Buy
875,410
+149,359
+21% +$342K ﹤0.01% 2727
2023
Q2 		$1.9M Buy
726,051
+593,872
+449% +$1.51M ﹤0.01% 2661
2023
Q1 		$215K Sell
132,179
-30,200
-19% -$37.8K ﹤0.01% 3874
2022
Q4 		$216K Buy
162,379
+5,124
+3% +$7.23K ﹤0.01% 4215
2022
Q3 		$245K Buy
157,255
+108,392
+222% +$179K ﹤0.01% 4390
2022
Q2 		$75K Sell
48,863
-100,183
-67% -$211K ﹤0.01% 4776
2022
Q1 		$382K Buy
+149,046
New +$364K ﹤0.01% 4526
2021
Q3 		– Sell
-261,488
Closed -$1.06M – 5277
2021
Q2 		$1.06M Sell
261,488
-723,828
-73% -$2.76M ﹤0.01% 3482
2021
Q1 		$4.44M Buy
985,316
+91,718
+10% +$495K ﹤0.01% 1939
2020
Q4 		$4.4M Buy
893,598
+57,301
+7% +$287K ﹤0.01% 1969
2020
Q3 		$4.96M Buy
836,297
+335,117
+67% +$1.34M 0.01% 1697
2020
Q2 		$1.33M Buy
501,180
+19,163
+4% +$66.7K ﹤0.01% 2724
2020
Q1 		$940K Buy
+482,017
New +$2.07M ﹤0.01% 2776

Other funds holding XERS

California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

David Shaw's XERS Position: Q2 2026 in Review

David Shaw increased its Xeris Biopharma Holdings (XERS) stake by 0.2% in Q2 2026, buying an estimated $102K and bringing the position to 7,804,758 shares worth $61.8M. The position accounts for 0.03% of the portfolio, ranked #657.

David Shaw first reported a position in XERS in Q1 2020 and has held it in 24 quarters since. 238 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • David Shaw held 7,804,758 shares of Xeris Biopharma Holdings worth $61.8M as of Q2 2026.
  • David Shaw bought 15,947 Xeris Biopharma Holdings shares in Q2 2026, an estimated $102K.
  • Xeris Biopharma Holdings made up 0.03% of David Shaw's portfolio in Q2 2026, its #657 holding.
  • David Shaw first reported a position in Xeris Biopharma Holdings in Q1 2020 and has held it in 24 quarters since.
  • 238 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.